Mehmood Khan

WISH 2024 Summit Closes with Qatar Becoming First MENA Country to Join Novartis Foundations Cardio4cities Initiative https://lnkd.in/duBTr5Ji HE Director of Public Health Department, Ministry of Public Health, Sheikh Dr. Mohammed bin Hamad Al-Thani explained "cardiovascular disease is the leading cause of death in Qatar. Noncommunicable diseases cost Qatar QR 18.1 billion annually, and CVDs account for 73 percent of that burden. "In many cases, CVDs are preventable, and that’s why we are committed to shifting our focus and approach to prevention, rather than only improving care this is especially important for chronic diseases, as most drivers of these diseases can be addressed outside of the health facilities, in our daily life. "This is exactly why we are eagerly looking forward to implementing CARDIO4Cities in Qatar, and working together with different sectors and stakeholders to improve cardiovascular health in the country." Speaking about the significance of Qatar joining this initiative, Research, Development, and Innovation Adviser to the Chairpersons Office and Executive Director of Research, Development and Innovation at Qatar Foundation (QF), Dr. Hilal Lashuel, said: "Participating in CARDIO4Cities offers Qatar unique opportunities to improve public health and drive innovation. Collaborating with a global network of cities allows us to share knowledge, learn from each other, and be inspired by new solutions developed in different urban settings. "This partnership will help us develop tools to capture, integrate, and analyze data, as well as scalable strategies to improve cardiovascular health at both the population and individual levels." He added that one of the programs key strengths is its tailored, data-driven approach, which adapts interventions to local needs. While fostering global collaboration, CARDIO4Cities ensures local ownership and prioritizes data privacy and security. Held under the theme 'Humanizing Health: Conflict, Equity, and Resilience', the two-day WISH 2024 summit brought together over 3000 delegates, including more than 200 global health leaders and expert speakers to discuss evidence-based ideas and practices in healthcare innovation to address the world’s most urgent global health challenges including the impact of conflict on healthcare, cancer, antimicrobial resistance, mental health and palliative care. (QNA)

92

2 Comments

With over 15 years of experience at Iovate, Raza Bashir shares his expertise in developing health-optimizing products supported by solid science and regulatory compliance. Watch the interview here: https://lnkd.in/e-NhurgU Key Highlights: Science-Backed Nutrition 🖇 : Emphasizing the importance of creating products backed by scientific research Caffeine Metabolism ⚡ : Highlighting genetic differences in caffeine metabolism and introducing Paraxanthine as a cleaner alternative for energy without the negative side effects. Muscle Health 💪 : Discussing the role of HMB free acid in preserving muscle mass during aging or injury, especially vital for women and aging adults. Industry Challenges 💡 : Addressing regulatory changes and public perception, such as the New York bill restricting supplement access for those under 18. #SportsNutrition #NutritionScience

28

Why Saudi Arabia is the Next Hub for Biotech and Pharma Companies: Insights from CPHI Riyadh Attending the recent CPHI Conference in Riyadh highlighted the immense potential Saudi Arabia holds for the biotech and pharmaceutical industries. As the Kingdom continues its transformative journey under Vision 2030, it’s clear that the region is positioning itself as a global leader in healthcare innovation and pharmaceutical excellence. Here’s why Saudi Arabia is becoming an increasingly attractive destination for biotech and pharma companies: 1. Strategic Vision and Government Support Vision 2030 emphasizes the development of a robust healthcare sector. With substantial government investments and initiatives aimed at fostering research and development, Saudi Arabia is creating an ecosystem that encourages innovation and collaboration in biotech and pharmaceuticals. 2. State-of-the-Art Infrastructure From advanced manufacturing facilities to research hubs, the Kingdom has invested in building world-class infrastructure to support the life sciences sector. This infrastructure not only enhances local production but also facilitates global partnerships. 3. Growing Market Demand With a rapidly expanding population and an increasing focus on chronic disease management, the demand for innovative therapeutics is at an all-time high. Saudi Arabia provides a unique opportunity for companies to tap into a high-growth market. 4. Regulatory Advancements The regulatory framework in Saudi Arabia has evolved to streamline approvals, making it easier for companies to introduce innovative products while ensuring patient safety. 5. Global Partnerships Events like CPHI Riyadh underscore the Kingdom’s commitment to fostering international collaborations. These platforms allow stakeholders to exchange knowledge, explore opportunities, and drive advancements in healthcare. Saudi Arabia is not just an emerging market; it’s a strategic partner for companies looking to innovate and grow in the biotech and pharma space. The discussions and insights from CPHI Riyadh reinforced the Kingdom’s immense potential. What are your thoughts on Saudi Arabia’s potential as a global leader in biotech and pharma? Feel free to share your insights or reach out if you’d like to discuss more. #CPHI2024 #Vision2030 #Biotech #Pharma #SaudiArabia #Innovation #HealthcareTransformation

54

The Kingdom of Saudi Arabia, represented by the Saudi Food and Drug Authority (SFDA), has been elected to be a member of the management committee for the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The ICH Management Committee (MC) is the body that oversees operational aspects of ICH on behalf of all Members, including administrative and financial matters and oversight of the Working Groups (WGs). The MC is responsible for submitting recommendations or proposals to the Assembly in preparation of Assembly discussions. https://lnkd.in/dsAEe5jE

844

90 Comments

The Saudi Food and Drug Administration (SFDA) published the guide to Good Manufacturing Practice for Natural Health Products. Country: Saudi Arabia #HealthcareInnovation #publishing #manufacturing #HealthAndWellness #Medical #regulatoryaffairs #sfda #healthcare #healthproducts #KSA

1

Learn more about how the MoU signed by DoH and Takeda, boosting clinical research and innovation, and facilitating regional advisory boards with expert panels to further advance knowledge sharing in the fields of rare diseases and oncology. Takeda Ahmed Fayed Mohammed Al-Bitar #AHealthierAbuDhabi #Healthcare #BIO2024

172

16 Comments

Tomorrow at 1:00 PM, join Dr. Abdelali Haoudi Managing Director of #KAIMRC’s Medical Biotechnology Park, for an in-depth session on strategies for advancing biotechnology both locally and globally. This is a unique opportunity to gain valuable insights from a leading expert who is shaping the future of the biotechnology sector. Don’t miss out on this chance to learn from one of the foremost leaders in the field. #RGMBS2024

16

We are proud to announce a strategic partnership between Genpharm and the Saudi Society of Dermatology and Dermatological Surgery. This collaboration aligns with Saudi Arabia's Vision 2030, reinforcing the Kingdom’s commitment to advancing healthcare, improving patient care, and fostering innovation in medical treatments. Together, Genpharm and #SSDDS will focus on enhancing healthcare professional education through Continuing Medical Education (#CME) programs and promoting the highest standards of care. This partnership reflects our shared dedication to supporting Vision 2030’s goal of transforming healthcare and creating a sustainable, world-class system that prioritizes the well-being of the Saudi population. Read the full press release here --> https://lnkd.in/eEjU3bAT   #SaudiVision2030 #HealthcareInnovation #DermatologyExcellence #Genpharm #SSDDS #CME #PatientCare #MedicalEducation

72

Celebrating the Launch of Adtralza and a New Partnership in Saudi Arabia Genpharm proudly marks a milestone with the launch of #Adtralza in Saudi Arabia, bringing new hope to patients with moderate to severe atopic dermatitis. In Riyadh, the event gathered healthcare professionals, dermatology experts, and partners, highlighting the commitment to improving eczema care. The event also witnessed the signing of a partnership between Genpharm and the Saudi Society for Dermatology and Dermatological Surgery, further strengthening efforts to advance dermatology care across the Kingdom. #Adtralza #AtopicDermatitis #EczemaCare #Dermatology #Genpharm #SaudiDermatology #JameelHealth"

22

Dr. Faheem Amin and his #NUST team developed a #nanocomposite for targeted delivery of Resveratrol to #breastcancer cells (MCF-7), enhancing stability with alginate-coated silver #nanoparticles. Elsevier | King Saud University | COMSATS University Islamabad | #NUSTResearch Read full research 👇 https://lnkd.in/eiwUwMAN

53

2 Comments

What a privilege to have an eye-opening, up-close "encounter" with the KSA advances in rare disease. I had the honour of being invited to Riyadh the previous year when they launched the "Moonshot for Rare" program but had no idea they were not only going to fire the rocket but to land the ship and start building. Having a vision and commitment fuelled by investment in science is putting KSA at the forefront of realizing the possibility of a better life for rare disease patients and families. Cornerstones: integrated and comprehensive Rare Disease programs from screening/diagnosis to optimal care; patient data platforms for collecting, integrating and using real-world, real-time data; evidence-informed, multi-stakeholder, multi-criteria decision-making for efficient and cost-effective access to medicines and other therapies. Special kudos to @Ahmed Aljedai and @Ali Asheri for such willingness to share knowledge and expertise.

45

1 Comment

𝐆𝐫𝐨𝐰𝐢𝐧𝐠 #Prebiotic 𝐈𝐧𝐠𝐫𝐞𝐝𝐢𝐞𝐧𝐭𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲: 𝐀 𝐇𝐞𝐚𝐥𝐭𝐡 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐏𝐞𝐫𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞 𝐆𝐞𝐭 𝐏𝐃𝐅📚 𝐂𝐨𝐩𝐲: https://lnkd.in/d4dySHDC The prebiotic ingredients market signifies a robust future, fueled by health consciousness and diverse applications in food and beverage sectors. The prebiotic ingredients market is experiencing rapid growth, this surge is driven by factors such as global population growth, increased use in nutraceuticals, and heightened awareness of health benefits. Our latest article delves into market segments, applications, and key industry players. 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐏𝐫𝐞𝐛𝐢𝐨𝐭𝐢𝐜𝐬: 𝐕𝐢𝐭𝐚𝐥 𝐟𝐨𝐫 𝐇𝐞𝐚𝐥𝐭𝐡 Inulin dominates the prebiotic market, sourced from chicory root, artichokes, and bananas. Consumed, inulin forms a gel in the stomach, aiding digestion, promoting fullness, and lowering cholesterol. Recommended daily intake ranges from 5g to 15g, supporting healthy digestion. 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐅𝐨𝐨𝐝 & 𝐁𝐞𝐯𝐞𝐫𝐚𝐠𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 Prebiotic ingredients play a crucial role in dairy, bakery, cereals, meats, and sports drinks. Inulin and fructooligosaccharides (FOS) enhance products like low-fat dairy and baked goods, improving taste, texture, and health benefits. Oligofructose replaces sugar in bread, facilitating gluten-free options with added health perks. Applications extend to convenience, functional, and infant foods, offering reduced calories, sugar content, and improved digestive health. 𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐒𝐨𝐮𝐫𝐜𝐞𝐬 𝐚𝐧𝐝 𝐇𝐞𝐚𝐥𝐭𝐡 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 Primary sources include chicory root, jicama, Jerusalem artichoke, and others rich in prebiotic fibers. Chicory root, especially high in inulin, supports pulmonary health and serves as a coffee alternative. 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐋𝐞𝐚𝐝𝐞𝐫𝐬 𝐚𝐧𝐝 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 Leading players such as Beneo, ADM, DuPont, Friesland Campina, and Ingredion drive market dynamics through innovative launches and expansions, reinforcing their global foothold.

5

SH Pharma has signed a strategic and commercial partnership with Dallah Pharma to sponsor and develop sales and marketing of SH Pharma products, starting from January 2025 for a period of four years in the private sector in the Kingdom of Saudi Arabia.

8

2 Comments

Saudi Arabia’s Healthcare & Biotech Ecosystem Map Like diligent students, Adam and I did the homework before I come to the region. As a supplement to the Healthcare Transformation report, which you can find here: https://lnkd.in/eG3eTeiw, I am excited to share the first version of the ecosystem map for anyone interested in Saudi Arabia. While I’m enjoying the beautiful weather, the warm waters of the Persian Gulf (I am in the UAE now), and the company of wonderful people, you can download a PDF with all the relevant links here: https://lnkd.in/eU7c2hkk WARNING!  Afterward, you might decide to visit and experience this vibrant, fast-moving ecosystem Btw if you find any gaps or notice that important companies are missing from this map, please let Adam or me know.   #healthcaretransformation, #SaudiArabia, #healthcare, #digitalhealth, #KSA, #biotech, #ecosystemmap, #digitaltransformation, #investments, #Vision2030

39

3 Comments

Check out our latest Pharmacoeconomics content on IVPN Pharmacoeconomics 💰💊

16

Another BIG step in the Saudi market

152

13 Comments

Unlock “The jigsaw of value approaches for innovative pharmaceutical products” with Dr. Hussain Al-Omar (Associate Professor of Pharmacoeconomics at King Saud University) Join us at MENAHTA Forum 2024 as we delve into the broad spectrum of health technology assessments. From understanding HTA principles to exploring diverse modalities and cost-containment strategies, it's a journey you won't want to miss. Register now and be part of the conversation shaping the future of healthcare! Follow MENAHTA Forum on LinkedIn for more updates! #MENAHTAForum #Pharmaexpert #MENAHTAForum2024 #Agenda #Pharmacoeconomics

7

𝗧𝗵𝗲 𝘄𝗼𝗿𝗹𝗱’𝘀 𝗺𝗼𝘀𝘁 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝗱𝗿𝘂𝗴 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝘁𝗲𝘀𝘁 𝗻𝗼𝘄 𝗳𝗶𝘁𝘀 𝗶𝗻 𝘆𝗼𝘂𝗿 𝘄𝗮𝗹𝗹𝗲𝘁. Drug Lab 118 has developed the most reliable and accurate instant drug detection test in the world, the “DRUGLAB”. A patented test, the DRUGLAB test is a discreet, credit card-sized test that detects drugs commonly used in drink spiking. Many of these drugs used for drink spiking—like 𝙠𝙚𝙩𝙖𝙢𝙞𝙣𝙚, 𝙂𝙃𝘽, 𝙍𝙤𝙝𝙮𝙥𝙣𝙤𝙡, 𝙖𝙣𝙙 𝙘𝙤𝙘𝙖𝙞𝙣𝙚—a chemical ingredient, called “𝘢𝘮𝘪𝘯𝘦𝘴.”   The test uses colorimetric chemistry (think color changes) to detect these substances in just 2-3 seconds—on any drink, any surface, anywhere.   Here’s what makes it 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲: → Simple to use, no training required. → Non-toxic and safe. → Portable and reliable.   This is the only 𝗽𝗮𝘁𝗲𝗻𝘁𝗲𝗱 𝘁𝗲𝘀𝘁 in the world that can detect almost all drugs containing amines ▼   ► This makes it effective for nearly every substance used in drink spiking.   𝗢𝘂𝗿 𝗴𝗼𝗮𝗹 is to provide people with a tool that empowers them to make quick, informed decisions about their safety.   If you still have questions about how it works, feel free to ask in the comments. I’d be happy to explain more.

18

2 Comments